|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | MA-SHS and SPS of ZrB2-ZrC composites显示文摘 | Takeshi Tsuchida Satoshi Yamamoto | 2004 | Solid State Ionics2004，177，： | 1 |
| 2 | Measurement of Land Syrface BRDF with Spatial Instability for Vicarious Calibration显示文摘 | Satoshi Tsuchida Isao Sato Shuhei Okada | 1999 | SPIE1999，3870，： | 1 |
| 3 | MA-SHS and SPS of ZrB 2 –ZrC composites显示文摘 | Takeshi Tsuchida Satoshi Yamamoto | 2004 | Solid State Ionics2004，，： | 1 |
| 4 | Organic LED full color passive-matrix display显示文摘 | Satoshi Miyaguchi Shinichi Ishizuka Takeo Wakimoto Jun Funaki Yoshinori Watanabe Hideo Ochi Tsuyoshi Sakamoto Takako Miyake Masami Tsuchida Isamu Ohshita Teruo Tohma | 2000 | Luminescence2000，8789，： | 1 |
| 5 | Prognostic factors in stage IB gastric cancer显示文摘AIM:To identify the subset of patients with stage IB gastric cancer with an unfavorable prognosis.METHODS:Overall survival(OS)rates were examined in 103 patients with stage IB(T1N1M0 and T2N0M0)gastric cancer between January 2000 and December2011.Univariate and multivariate analyses were performed to identify risk factors using a Cox proportional hazards model.RESULTS:The OS rates of patients with T1N1 and T2N0 cancer were 89.2%and 94.1%at 5-years,re-spectively.Both univariate and multivariate analyses demonstrated that tumor location was the only significant prognostic factor.The OS rate was 81.8%at5-years when the tumor was located in the upper third of the stomach and was 95.5%at 5-years when the tumor was located in the middle or lower third of the stomach(P=0.0093).CONCLUSION:These data may suggest that tumor location is associated with survival in patients with stage IB gastric cancer. | Toru Aoyama Takaki Yoshikawa Hirohito Fujikawa Tsutomu Hayashi Takashi Ogata Haruhiko Cho Takanobu Yamada Shinichi Hasegawa Kazuhito Tsuchida Norio Yukawa Takashi Oshima Mari S Oba Satoshi Morita Yasushi Rino Munetaka Masuda | 2014 | World Journal of Gastroenterology2014，20，21： | 1 |
| 6 | An Overview of Regular Dialysis Treatment in Japan (As of 31 December 2010)显示文摘 | Shigeru Nakai Kunitoshi Iseki Noritomo Itami Satoshi Ogata Junichiro James Kazama Naoki Kimata Takashi Shigematsu Toshio Shinoda Tetsuo Shoji Kazuyuki Suzuki Masatomo Taniguchi Kenji Tsuchida Hidetomo Nakamoto Hiroshi Nishi Seiji Hashimoto Takeshi Hasegaw | 2012 | Therapeutic Apheresis and Dialysis2012，，6： | 1 |
| 7 | MA-SHS and SPS of ZrBz-ZrC Composites显示文摘 | Takeshi Tsuchida Satoshi Yamamoto | 2004 | SolidState lonics2004，172，： | 1 |
| 8 | Dose escalation of external beam radiotherapy for high-risk prostate cancerdImpact of multiple high-risk factor显示文摘Objective:To retrospectively investigate the treatment outcomes of external beam radiotherapy with androgen deprivation therapy(ADT)in high-risk prostate cancer in three radiotherapy dose groups.Methods:Between 1998 and 2013,patients with high-risk prostate cancer underwent threedimensional conformal radiotherapy or intensity-modulated radiotherapy of 66 Gy,72 Gy,or 78 Gy with ADT.Prostate-specific antigen(PSA)relapse was defined using the Phoenix definition.PSA relapse-free survival(PRFS)was evaluated in each radiotherapy dose group.Moreover,high-risk patients were divided into H-1(patients with multiple high-risk factors)and H-2(patients with a single high-risk factor)as risk subgroups.Results:Two hundred and eighty-nine patients with a median follow-up period of 77.3 months were analyzed in this study.The median duration of ADT was 10.1 months.Age,Gleason score,T stage,and radiotherapy dose influenced PRFS with statistical significance both in univariate and multivariate analyses.The 4-year PRFS rates in Group-66 Gy,Group-72 Gy and Group-78 Gy were 72.7%,81.6%and 90.3%,respectively.PRFS rates in the H-1 subgroup differed with statistical significance with an increasing radiotherapy dose having a more favorable PRFS,while PRFS rates in H-2 subgroup did not differ with increase in radiotherapy dose.Conclusion:Dose escalation for high-risk prostate cancer in combination with ADT improved PRFS.PRFS for patients in the H-1 subgroup was poor,but dose escalation in those patients was beneficial,while dose escalation in the H-2 subgroup was not proven to be effective for improving PRFS. | Rei Umezawa Koji Inaba Satoshi Nakamura Akihisa Wakita Hiroyuki Okamoto Keisuke Tsuchida Tairo Kashihara Kazuma Kobayashi Ken Harada Kana Takahashi Naoya Murakami Yoshinori Ito Hiroshi Igaki Keiichi Jingu Jun Itami | 2019 | Asian Journal of Urology2019，6，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员